48 results about "Mitochondrial electron transport" patented technology

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof

and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, an N-oxide, or a salt thereof, Formula (1) and (b) at least one invertebrate pest control agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

The invention relates to a microbial fuel cell, in particular to a green algae biological fuel cell generating power on the basis of photosynthesis, which comprises a transparent cathode cell of green algae culture solution and an anode cell containing rich oxygen or oxidant solution, wherein the cathode cell and the anode cell are isolated by a proton exchange membrane; the cathode and anode of the cell are fixed in the cathode cell and the anode cell respectively; the cathode cell is isolated from the air to create an anaerobic environment in the cathode cell, hydrogen-generating green algae is used a system green algae material, an indirect-process hydrogen generation regulating technique is adopted, an electronic transfer mediator is added into the system to enable electrons which aregenerated by photosynthesis to be combined with the electronic mediator through an electron transport chain before reaching hydrogenase, the electronic mediator releases electrons at a cathode electrode, and the electrons are transferred to the anode to combine with protons passing through the proton exchange membrane and oxidant in the cathode cell to form water. In the invention, optical energycan be converted into electric energy by coupling the photosynthesis of microalgae and a cell system, and a novel biological fuel cell is provided.

The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells. (Formula I) (I)

The invention discloses a pure organic D-pi-A type photosensitive dye as well as a preparation method and application thereof. The photosensitive dye is a triphenyl pyrrole D-pi-A type photosensitive dye with 1, 2, 5-triphenyl pyrrole as an electron donor group, styrene as an electron transport chain and cyanoacetic acid as an electron withdrawing group. The preparation method comprises the following steps: under the protection of argon, adding p-formylphenyl styrene, 1-(p-bromophenyl)-2, 5-diphenyl pyrrole, palladium acetate, tetrabutyl ammonium bromide and tri (o-methyl phenyl) phosphorus into a mixed solution of N, N'-dimethylformamide and trimethylamine to prepare 4-(4-(2, 5-diphenyl pyrrole) styryl) benzaldehyde, serving as an intermediate, and then preparing the pure organic D-pi-A type photosensitive dye by virtue of the intermediate. The pure organic D-pi-A type photosensitive dye is simple in synthesis route, low in cost, high in molar extinction coefficient serving as a dye-sensitizer for preparing a solar cell, difficult in desorption and beneficial to prolonging the whole service life of the battery.

The invention mainly relates to a method for controlling a common roll girder, and belongs to the electric control technical field of common-type roll grinders. The method is characterized in that a PLC programmable logic controller (1) is not only connected with a programmable terminal display (2) through a PROFBUS data bus, but also connected with a control unit (3) through the data bus; the control unit (3) is connected with a servo driver (4) and a manual pulse generator (5) through the data bus. The invention has the advantages that the S7-300 PLC programmable controller is utilized, the logic control of the programmable controller is adopted, and the manual pulse generator is adopted instead of a mechanical hand wheel so as to reduce the labor intensity of an operator. At the same time, the programmable terminal display is mounted for displaying the movable distance on each coordinate axis; the accurate tool advancement and alignment on a common roll grinder is realized; an electron transport chain is adopted instead of the mechanical transmission chain, so as to greatly improve the working efficiency and reduce the labor intensity of an operator.

The invention discloses a pesticide composition with a synergistic effect, which comprises two active components with the weight portion ratio of between 1:100 and 100:1, wherein the first active component is selected from 3-bromo-N-[4-chloro-2-methyl-6-[amino carbonyl] phenyl]-1-(3-chloro-2-pyridyl)-1H-pyrazole-5-amide or N-oxide or a salt thereof; and the second active component is selected from any one of the following compounds with insecticidal activity: aryl pyrazoles, neonicotines, organic phosphoruses, carbamates, pyrethroids, benzoyl ureas, acylhydrazines, macrolide antibiotics, pyrroles, thioureas, Ryanicide receptor-ligands, mitochondrial electron transport inhibitors, nereistoxins, pyridalyls, indoxacarbs or Bacillus thuringiensis, or salts thereof.

A transgenic fly whose genome is modified to express enhanced levels of glutamate-cysteine ligase (GCL) gene is provided. The fly displays phenotypes associated with Alzheimer's disease (AD). Further, a method for diagnosing AD is provided, which includes assessing enzymatic activities in mitochondrial enzymes. Glutathione pathway are investigated by creating Alzheimer's model Drosophila with over-expression of the GCLc gene, inducing redox stress through sleep deprivation, and analyzing mitochondrial electron transport chain (ETC) using colorimetric enzymatic assays. For prevention of AD, it is proposed that the epigenetic approaches be used to increase glutathione levels in vivo before the onset of AD. For treatment of AD, it is proposed that the glutathione levels be increased by GCLc modulation.

The present disclosure relates to pharmaceutical compositions containing electron transport chain (ETC) inhibitors, which are capable of promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.

A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.

The present invention provides a universal system that detects cancer cells at all stages including early developmental stages as well as matured cancerous tumors. The system relates to monitoring the environment surrounding abnormally metabolizing cells, e.g., predominantly glycolytic cells, cancerous cells, precancerous cells, and/or cells with reduced mitochondrial Electron Transport Chain activity. Nanosensors detect chemical signatures of the organic compounds released by cancer cells into bodily fluids or to the air to detect cancerous or precancerous metabolisms in samples such as urine, saliva, sweat, blood or breath. Treatments provided in recognition of the signature metabolic changes occurring in cancer cells target the abnormal metabolism generally with special emphasis relating to changed mitochondrial metabolism and cell survivability. The treatments include, but are not limited to: therapeutic compositions and methods for treating, delaying, slowing or preventing one or more cancers.

A method and device for stimulating a dysfunctional mitochondria in a human brain afflicted with a neurological disorder by stimulating the dysfunctional mitochondria at more than one level of its electron transport chain by co-administering more than one type of external stimulation such as the co-administration of both light and a therapeutic agent such as vitamin K2.

The invention belongs to the technical fields of biology and medicine, and particularly relates to application of Nano-MitoPBN in preparing medicines for resisting oxidation and treating diabetes. Dueto the micro-compartmentalization effect, Nano-MitoPBN can remove mitochondrion superoxide/hydrogen peroxide generated by single electron leakage of a liver mitochondrion electron transport chain, increase the respiration rate of a mitochondrion state 3 and the respiration control ratio, improve synthesis of ATP, and promote the function of mitochondria. In addition, by reducing ROS, Nano-MitoPBNreduces gluconeogenesis, increases glycolysis, reverses ROS-mediated liver glycometabolism reprogramming in diabetic animals, then reduces the peripheral blood glucose level of the diabetic animals and restores the glucose tolerance of the diabetic animals. Nano-MitoPBN serves as a material for preparing the medicines for treating diabetes, can be used for targeting liver prevention and relievingand treating diabetes, and can obtain a remarkable curative effect with a very small dosage.

The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.

The present disclosure relates to exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers and diagnostic and prognostic methods for depression, psychosis and schizophrenia. The disclosure also provides compositions for detecting exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers in biological samples as well as compositions and methods useful for treating depression, psychosis and schizophrenia.

Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

The invention relates to application of deferoxamine mesylate in preparation of antitumor drugs. In-vitro experiments prove that the deferoxamine mesylate (DFO) can inhibit proliferation of liver cancer cells in vitro; and a mouse-borne tumor test proves that 100 mg/kg of the DFO is a safe dosage for mice, and the growth of xenotransplantation tumors can be inhibited with the dosage. In-vivo and in-vitro test results are consistent to show that the DFO can reduce iron load of hepatoma carcinoma cells and inhibit proliferation of hepatoma carcinoma cells, and has an anti-tumor effect. The anti-tumor action mechanism of the DFO is further studied, and it is found that the DFO reduces the iron content of cells, mitochondrial dysfunction is caused by destroying a mitochondrial structure and a mitochondrial respiration electron transport chain, so cell energy metabolism is affected, and liver cancer cell proliferation is inhibited; and meanwhile, the DFO can retard the progress of a tumor cell cycle, so HCC proliferation and tumor growth are inhibited. The invention provides the novel medical application of deferoxamine mesylate.